More is less: Glucocorticoid-sparing agents in polymyalgia rheumatica
5 affiliations
- 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
- 2Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
- 3Epidemiology and Health Services Research, German Rheumatism Research Center (DRFZ), A Leibniz Institute, Berlin, Germany
- 4Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin, Berlin, Germany
- 5Translational Rheumatology, German Rheumatism Research Center (DRFZ), A Leibniz Institute, Berlin, Germany
Abstract
Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatic diseases in older adults. Glucocorticoids (GC) are very effective in treating PMR, but their use is associated with adverse events such as infections, osteoporosis or ophthalmological diseases. In patients with relapsing PMR and long-term GC dependency or those with an initial high risk of GC-related toxicity, GC-sparing agents can be used to minimize GC exposure. Several substances have been tested in clinical trials. Methotrexate was commonly used in the past decades, but the interleukin (IL)-6 receptor inhibitor sarilumab is the first (and currently only) GC-sparing agent approved for use in PMR in the United States and Europe. Sarilumab was able to decrease cumulative GC exposure and increase the probability of achieving remission in a recent trial. In the foreseeable future, janus kinase inhibitors and IL-17 inhibitors might join the treatment armamentarium of GC-sparing agents in PMR. Additionally, the 11β-hydroxysteroid dehydrogenase type 1 inhibitor clofutriben has shown promise in protecting against GC toxicity. This review summarizes real-world evidence on GC use and associated toxicity in patients with PMR, puts data from relevant trials into context and explores future directions in the treatment of patients with PMR.
Related
- P076 Spontaneous remission of polymyalgia rheumatica without treatment
- P070 Polymyalgia rheumatica; but what lay silent in the shadows?
- P085 Polymyalgia rheumatica and late-onset axial spondyloarthritis: recognising diagnostic overlap
- OA12 When steroids may not be the answer in polymyalgia rheumatica
- The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica
BibTeX
@article{palmowski2026more,
title = {{More is less: Glucocorticoid-sparing agents in polymyalgia rheumatica}},
author = {Andriko Palmowski and Frank Buttgereit and Anja Strangfeld and Zhivana Boyadzhieva},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2026},
month = sep,
doi = {10.1177/1759720x261480000},
url = {https://doi.org/10.1177/1759720x261480000},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - More is less: Glucocorticoid-sparing agents in polymyalgia rheumatica
AU - Andriko Palmowski
AU - Frank Buttgereit
AU - Anja Strangfeld
AU - Zhivana Boyadzhieva
PY - 2026
DA - 2026/09/15
JO - Therapeutic Advances in Musculoskeletal Disease
DO - 10.1177/1759720x261480000
UR - https://doi.org/10.1177/1759720x261480000
AB - Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatic diseases in older adults. Glucocorticoids (GC) are very effective in treating PMR, but their use is associated with adverse events such as infections, osteoporosis or ophthalmological diseases. In patients with relapsing PMR and long-term GC dependency or those with an initial high risk of GC-related toxicity, GC-sparing agents can be used to minimize GC exposure. Several substances have been tested in clinical trials. Methotrexate was commonly used in the past decades, but the interleukin (IL)-6 receptor inhibitor sarilumab is the first (and currently only) GC-sparing agent approved for use in PMR in the United States and Europe. Sarilumab was able to decrease cumulative GC exposure and increase the probability of achieving remission in a recent trial. In the foreseeable future, janus kinase inhibitors and IL-17 inhibitors might join the treatment armamentarium of GC-sparing agents in PMR. Additionally, the 11β-hydroxysteroid dehydrogenase type 1 inhibitor clofutriben has shown promise in protecting against GC toxicity. This review summarizes real-world evidence on GC use and associated toxicity in patients with PMR, puts data from relevant trials into context and explores future directions in the treatment of patients with PMR.
SN - 1759-720X
SN - 1759-7218
ER -